Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p<0.0001) maintenance of function at six ...

Organogenesis (NASDAQ:ORGO) stock rose ~33% on Thursday after Q1 results prompted the company to raise its FY23 revenue outlook. Net loss widened to -$2.97M, compared to $0.9M in Q1 2022.

Organogenesis Holdings Inc (NASDAQ: ORGO) reported Q1 revenues of $107.6 million, up 11% Y/Y, beating the consensus of $95.50 million. The increase in net revenue was driven by a 12% increase in ...

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Organogenesis Holdings (ORGO – Research Report), with a price target of $6.00. Ryan Zimmerman has given his Buy ...

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

There have been no specific sales or earnings guidance reported for Organogenesis Hldgs in recent months. Browse guidance and forecast on all stocks.

For ages now, plants have been the primary source of nutrition for animals and mankind. Additionally, plants are used for the ...

CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization ...